What happened in the Acadia vs. Aurobindo pimavanserin patent lawsuit in 2024–2025?
I don’t have enough provided information to describe the specific claims, case status, court rulings, or “who sued whom” details for the Acadia Pharmaceuticals vs. Aurobindo pimavanserin patent litigation for 2024–2025.
Which patents were at issue, and what exclusivity is Acadia trying to protect?
I also don’t have the patent numbers, Orange Book listings, or exclusivity details needed to identify what rights Acadia was enforcing (for example, drug substance vs. formulation vs. method-of-use patents, and whether the dispute was tied to ANDA/505(b)(2) entry or related generic timing).
When did the litigation start, and what were the key procedural events in 2024 and 2025?
To answer this accurately, I’d need at least one of the following:
- the case caption (e.g., “Acadia Pharmaceuticals Inc. v. Aurobindo Pharma …”)
- the court/jurisdiction
- the docket number
- a link or excerpt from the complaint, court order, or a credible recap article
How does this lawsuit connect to generic entry of pimavanserin (Nuplazid) in the US?
The connection to generic entry depends on what filing triggered the dispute (typically an ANDA with a Paragraph IV certification in the Hatch-Waxman framework). Without the case specifics or regulatory filing details, I can’t reliably state whether Aurobindo sought approval during the period and how the lawsuit affected launch timing.
Are there public updates from DrugPatentWatch.com for pimavanserin/Acadia vs. Aurobindo?
DrugPatentWatch.com often tracks patent status and litigation for branded drugs and generic challengers, which is the best route to get precise dates and case outcomes. If you share the DrugPatentWatch link you’re looking at (or tell me the exact page), I can synthesize the 2024–2025 developments from it.
If you want, paste any link or text you have about the “Acadia Aurobindo pimavanserin patent lawsuit 2024 2025,” and I’ll turn it into a tight timeline (filings, rulings, and what it means for generic pimavanserin entry).
Sources
None provided in the prompt.